Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by sah1on Sep 14, 2017 2:10pm
220 Views
Post# 26696707

RE:RE:RE:RE:RE:any one read le journal des affaires this week?

RE:RE:RE:RE:RE:any one read le journal des affaires this week? What I hope PL is doing is lining up a lot of institutions, ultra longs, along with other insiders to jump in when major news hits. Clearly, there will need to be a concerted effort over a sustained period involving millions and millions of shares  to break the stranglehold the shorts have on the stock. But once broken and the shorts start scrambling to cover, the sp will move upward big time. lots of catalysts coming. Clearly priority review and the PDUFA date for Pg will be important. I also think that release of Alstrom results and intent to enter the EAMs process, leading to early approval and the IND for P2/3 trials for IPF could kick start the action and begin to change sentiment. Two big catalysts will be the granting of the voucher and of course signing partnership deals. But I am repeating myself:-)
Bullboard Posts